tbuckley/cabot-search huggingface dataset:
Abstract 16693: Heart Failure in the Caribbean: Phenotypes and Management Patterns
Authors: Edisson Feliz, Samuel Guzman, Jennifer Mateo, Angelica Rumardo, Elaine Nunez Ayala, Cesar Herrera
Journal: Circulation (2020)

Introduction: There is sparse published data on Heart Failure (HF) in the Caribbean region where cultural, ethnic and socioeconomical differences may play a role in all aspects of this entity. We sought to study clinical profiles and treatment characteristics of patients with HF in the Dominican Republic. Methods: Electronic records of a tertiary care CV center were used to recruit stable patients with HF from the outpatient cardiology clinic and immediately post hospital discharge. Results: From May 2015 to May 2020, 700 consecutive subjects with any form of HF were identified: 478 (68%) with Heart Failure with Reduced Ejection Fraction (HFrEF), 144 (21%) with Heart Failure with Mid Ejection Fraction (HFmEF) and 78 (11%) with Heart Failure with Preserved Ejection Fraction (HFpEF) constitute the study group; 391 (56%) were enrolled immediately post-discharge and 309 (44%) from the outpatient clinic. Gender (male): HFrEF 66% / HFmEF 63% / HFpEF 46% (p=0.003); mean age: 65±14 / 66±14 / 77±11 yrs. (p=0.01). Comorbidities: Hypertension 83% / 88% / 97% (p=0.002); Diabetes Mellitus 36% / 42% / 40% (p=0.45); Coronary Artery Disease 45% / 51% / 26% (p=0.009); Atrial fib 23% / 20% / 40% (p=0.002); CKD 23% / 20% / 40% (p=0.002). Etiology by clinical assessment: Ischemic Heart Disease 48% / 58% / 17%; Cardiomyopathies 32% / 15% / 0%; Hypertensive 5% / 9% / 83%; others 15% / 18% / 0% (all p=&lt;0.001). Echo: Ejection Fraction (EF) 29±7% / 44±3% / 62±8%; mitral regurgitation ≥ moderate 30% / 15% / 8% (all p=&lt;0.001). Management patterns for HFrEF: ACE inhibitors/Angiotensin II receptor blockers (ARB) 66%; Sacubitril/Valsartan 14%; aldosterone receptor antagonists (ARA) 63%; beta blockers (BB) 91%. On guideline-directed drugs at target doses: ARB/ACE/Sacubitril-valsartan 33%; BB 22%; and ARA 72%. Device use in eligible patients: ICD/CRT/CRT-D 17%. Conclusions: In this series, HFrEF was the most common form with suboptimal Guideline-directed therapy in many subjects, particularly device use. Those with HFmEF shared similarities with HFrEF in etiologies. Patients with HFpEF were older, more frequently women, and had a higher prevalence of CKD and Atrial Fib. Regional registries ought to better characterize the impact of these findings on outcomes among high-risk populations.
Uncommon hepatitis C virus among migrant sex workers in Chiangmai, Thailand
Authors: Sayamon Hongjaisee, Woottichai Khamduang, Patumrat Sripan, Sirinath Choyrum, Viraporn Thepbundit, Natthapol Kosashunhanan, Nicole Ngo-Giang-Huong, Arunrat Tangmunkongvorakul
Journal: Clinical Microbiology and Infection (2021)
117P Pretherapeutic neutrophil-lymphocyte ratio as prognostic and predictive factors in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
Authors: P. Rottier, A. Da Silva, C. Levy, D. Allouache, A.C. Johnson, I. Hrab, A. Faveyrial, K. Gunzer, C. Segura Djezzer, A. Morel, M. Villemin, C. Boscher, L. Boismoreau, F. Cherifi, J. Lequesne, G. Emile
Journal: Annals of Oncology (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Authors: David S. Khoury, Deborah Cromer, Arnold Reynaldi, Timothy E. Schlub, Adam K. Wheatley, Jennifer A. Juno, Kanta Subbarao, Stephen J. Kent, James A. Triccas, Miles P. Davenport
Journal: Nature Medicine (2021)
Abstract 15565: Long-term Dietary and Weight Changes Following a Short-term Dietary Intervention Study: 4-year Follow-up of the Evade Cad Trial
Authors: Siddhant Dogra, Alec Getz, Kathleen Woolf, Jonathan D Newman, Yuhe Xia, James Slater, Binita Shah
Journal: Circulation (2020)

Introduction: The randomized EVADE CAD trial demonstrated greater reduction in high sensitivity C-reactive protein and LDL-cholesterol with a vegan vs. AHA-recommended diet in patients with coronary artery disease on guideline-directed medical therapy. The 8-week intervention included provision of groceries, cooking tools, and regular contact with a registered dietitian. Methods: Trial participants underwent telephone follow-up to obtain self-reported dietary adherence, 24-hour dietary recall, self-reported weight, and major adverse cardiovascular events (MACE). Supporting medical documents for MACE were reviewed by investigators. Results: Two participants in the vegan arm withdrew during the trial leaving 98 participants available for follow-up. The vegan group reported significantly lower dietary adherence at all follow-ups when compared to the AHA group; however, adherence rates were numerically higher in both groups when assessed by 24-hour dietary recall vs. self-report (F1A-B). The two groups did not differ in self-reported rating of the healthiness of their current diet (F1C). Both groups continued to have significantly lower weight when compared to baseline up to 3 years follow-up, but only the vegan group remained lower at year 4. Percent weight lost from baseline did not differ between groups. Cumulative MACE incidence also did not differ between groups (F2). Conclusions: Although the vegan diet was not sustainable long-term when compared to the AHA-recommended diet, both groups did not differ in self-reported rating of the healthiness of their current diet or incidence of MACE and had sustained weight loss after the active intervention was complete.
Literature review and recommendations for clinical application of small-bowel capsule endoscopy, based on a panel discussion by international experts
Authors: K. Mergener, T. Ponchon, I. Gralnek, M. Pennazio, G. Gay, W. Selby, E. Seidman, C. Cellier, J. Murray, R. de Franchis, T. Rösch, B. Lewis
Journal: Endoscopy (2007)

Corrected by: Literature review and recommendations for clinical application of small-bowel capsule endoscopy, based on a panel discussion by international expertsEndoscopy 2007; 39(12): 1105-1106DOI: 10.1055/s-2007-995377
Comorbidities, mortality and survival in patients with pyoderma gangrenosum: a Danish nationwide registry‐nested case–control study*
Authors: H. Ben Abdallah, R. Bech, K. Fogh, A.B. Olesen, C. Vestergaard
Journal: British Journal of Dermatology (2021)

Pyoderma gangrenosum (PG) is an ulcerative skin disease associated with comorbidities and increased mortality; however, the literature on this topic is scarce.To investigate the mortality, prevalence and risk of comorbidities in patients with PG.This nationwide registry nested case-control study included all inpatients and outpatients diagnosed with PG in tertiary dermatology centres in Denmark between 1 January 1994 and 31 December 2016. Each case was matched on date of birth and sex with 10 unique controls. The Danish National Patient Registry was used to identify all patients and to gather information on comorbidity. Information on age, sex, vital status and emigration was obtained from the Danish Civil Registration System. The outcomes were 19 different comorbidities and all-cause mortality. Prevalence was assessed from odds ratios (ORs) for specific comorbidities at the time of PG diagnosis. The risk of developing specific comorbidities and death was assessed using hazard ratios (HRs) obtained using the Cox proportional-hazards model.A total of 1604 patients with PG were matched with 16 039 controls. Some associations were known, e.g. inflammatory bowel disease [OR 19·15 (15·27-24·02), HR 6·51 (4·24-10·01)], while others have not been described previously, e.g. osteoporosis [OR 1·57 (1·22-2·02), HR 2·59 (2·08-3·22)]. Mortality was significantly increased among patients with PG [HR 2·79 (2·57-3·03)].Patients with PG have increased mortality and an increased prevalence and risk of both previously reported and novel comorbidities that may have severe consequences if left undiagnosed. Our findings are mainly related to moderate and severe PG.
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis
Authors: Sunny Z. Wu, Daniel L. Roden, Ghamdan Al-Eryani, Nenad Bartonicek, Kate Harvey, Aurélie S. Cazet, Chia-Ling Chan, Simon Junankar, Mun N. Hui, Ewan A. Millar, Julia Beretov, Lisa Horvath, Anthony M. Joshua, Phillip Stricker, James S. Wilmott, Camelia Quek, Georgina V. Long, Richard A. Scolyer, Bertrand Z. Yeung, Davendra Segara, Cindy Mak, Sanjay Warrier, Joseph E. Powell, Sandra O’Toole, Elgene Lim, Alexander Swarbrick
Journal: Genome Medicine (2021)

High throughput single-cell RNA sequencing (scRNA-Seq) has emerged as a powerful tool for exploring cellular heterogeneity among complex human cancers. scRNA-Seq studies using fresh human surgical tissue are logistically difficult, preclude histopathological triage of samples, and limit the ability to perform batch processing. This hindrance can often introduce technical biases when integrating patient datasets and increase experimental costs. Although tissue preservation methods have been previously explored to address such issues, it is yet to be examined on complex human tissues, such as solid cancers and on high throughput scRNA-Seq platforms.
Abstract 11954: Readmission After Discharge Against Medical Advice for Persons With Opioid-Associated Infective Endocarditis
Authors: Asher J Schranz, Li-Tzy Wu, David Wohl, David L Rosen
Journal: Circulation (2019)

Background: Infective endocarditis (IE), an increasingly-recognized consequence of the opioid epidemic, is linked to frequent discharge against medical advice (DAMA). We characterized readmissions ...
Abstract 17005: Early Goal Directed Fluid Therapy for Patients With Heart Failure and Septic Shock
Authors: Pedro Torres, Baher Al Abassi, Mohamed Abdul Qader, Riya Job, Kai Chen, Fergie Ramos Tuarez, Robert Chait, Jesus E Pino
Journal: Circulation (2020)

Introduction: The use of aggressive fluid therapy in patients with heart failure and reduced ejection fraction (HFrEF) who develop septic shock is controversial. Methods: This is a retrospective cohort study of 334 patients with heart failure (HF) and septic shock admitted to a tertiary cardiovascular center between 01/2015 and 06/2018. For this study, ejection fraction (EF) was dichotomized into &lt;45% (HFrEF) and ≥45% (HF with preserved EF). The evaluated outcomes included in-hospital mortality, development of pulmonary edema, cardiogenic shock, and 30-day readmission rate. Results: A total of 133(40%) patients had HFrEF, and 201(60%) patients had HFpEF (see Table 1, baseline characteristics). Early goal direct fluid therapy and vasopressors were equally implemented in all patients with HF that developed septic shock. Outcomes: There was no difference in in-hospital mortality for patients with HFrEF that developed septic shock when compared to patients with HFpEF, 64(48%) vs 102(51%) p=0.6542. Patients with HFrEF had a higher incidence of cardiogenic shock 25(19%) vs 9(4.5%) p&lt;0.0001 and 30-day HF-related readmission 25(36%) vs 17(17%) p=0.0096. However, pulmonary edema requiring urgent intravenous diuresis 82(62%) vs 113(56%) p=0.4186 or mechanical ventilation 70(53%) vs 110(55%) p= 0.6543 was similar between groups. Conclusions: Once patients with HF develop septic shock, the mortality is similar for both HFrEF and HFpEF. However, complications such as cardiogenic shock and 30-day readmission are more common in patients with HFrEF. A more individualized treatment approach is needed for this population.
Abstract P204: Tobacco Use And The AHA 2030 Impact Goals: A Simulation
Authors: Douglas Levy, Sydney L Goldberg, Emily P Hyle, Krishna P Reddy
Journal: Circulation (2021)

Background: The AHA’s 2030 Impact Goals seek to increase population health-adjusted life expectancy (LE) by 2y. Tobacco is a top contributor to all-cause mortality and cardiovascular disease (CVD). We estimated the potential contribution of improved tobacco control to achieve the 2030 Impact Goals in the US. Methods: We used the validated STOP microsimulation model with NHIS estimates of age- and sex-stratified mortality and CVD incidence to project changes in LE, as well as 10y, 20y, and lifetime CVD cumulative incidence, if cigarette smoking declined among the current US population. We assessed the impact of preventing initiation (current v never smokers) or increasing cessation (current v former smokers) at different ages. To examine the maximum impact of population-wide cessation, we projected changes in population LE and CVD incidence if smoking prevalence among those ≥20yo went immediately to 0%. Results: Preventing smoking initiation increases LE by 10.2y (men [M]) and 9.1y (women [W]) and reduces lifetime CVD incidence by 16.8% (M) and 26.2% (W) compared to lifetime smoking. Even cessation at age 60 extends LE by 3.7y (M) and 2.5y (W) and reduces 10y CVD incidence by 39.1% (M) and 59.4% (W) (Table). Total elimination of cigarette smoking in the 2020 US population aged ≥20y (e.g. by outlawing cigarettes) would increase the cohort LE by 0.4 (M) and 0.2 (W) years and reduce 20y CVD incidence by 6.0% (M) and 7.0% (W). Conclusion: Preventing smoking initiation offers the greatest benefit, but cessation at any age substantially improves LE and reduces CVD risk. The modest potential contribution of tobacco elimination to achieving the 2030 Impact Goals is due to already low smoking prevalence: &lt;14% (projected) in 2020.
Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy
Authors: Yolla El Dakdouki, Jean-Marie Michot, Julien Lazarovici, Khalil Saleh, David Ghez, Claude Chahine, Loic Verlingue, Christophe Willekens, Veronique Vergé, Christophe Ferme, Alina Danu, Vincent Ribrag
Journal: Blood (2017)
Abstract MP59: Effects Of Sodium Reduction And Weight Loss On Lightheadedness And Falls In Older Adults: Results From TONE
Authors: Stephen P Juraschek, Jennifer Cluett, Timothy Anderson, Anthony Ishak, Shivani Sahni, Courtney Millar, Lawrence J Appel, Edgar R Miller, Lewis Lipsitz, Kenneth J Mukamal
Journal: Circulation (2021)

Background: The Trial of Nonpharmacologic Interventions in the Elderly (TONE) demonstrated the efficacy of sodium reduction and weight loss to reduce hypertension medication use in older adults. However, adverse events related to lightheadedness and falls have not been reported. Objective: To determine whether sodium reduction and weight loss are associated with greater risk of lightheadedness and falls among older adults. Methods: TONE was a randomized trial of 60-80 year-old adults with systolic BP (SBP) and diastolic BP (DBP) below 145 and 85 mm Hg, respectively, while receiving treatment with a single antihypertensive medication. Participants were randomized to behavioral interventions focused on sodium reduction, weight loss, both, or neither (usual care); 3 months after randomization, the antihypertensive medication was withdrawn and only restored later during the study if needed for uncontrolled hypertension. Total follow-up was 36 months post-randomization. Two physicians independently adjudicated adverse event logs, masked to intervention assignment. The primary outcome was a composite of the first occurrence of adverse event related to falls (total N=95): 72 involved orthostatic symptoms (lightheadedness, dizziness, vertigo), while 23 involved hard events (fall or syncope). Hazard ratios were determined via Cox proportional hazards models. Results: Among the 975 participants (mean age 66 yrs, 48% women, 24% black), mean SBP and DBP were 128 and 71 mm Hg. The cumulative incidence of adverse events at 30 months was 0.08, 0.13, 0.11, and 0.14 for usual care, reduced sodium, weight loss, or both, respectively ( Figure ). In adjusted multi-variable analyses, sodium reduction was associated with higher risk of an adverse event (HR 1.52; 95% CI: 1.02, 2.27), while weight loss was not associated with adverse events (HR 1.18; 0.77, 1.79). Conclusions: In the context of antihypertensive medication withdrawal, sodium reduction was associated with a higher risk of fall-related adverse events, predominantly symptoms.
MRI of the Heart in Obstructive Hypertrophic Cardiomyopathy: Scanning Protocol, Visualization, Clinical Significance (review of the Literature with Own Clinical Observations)
Authors: S. V. Shayakhmetova, A. V. Afanasyev, A. V. Bogachev-Prokofiev
Journal: Radiology - Practice (2021)

Hypertrophic cardiomyopathy (HCM) defined by wall thickness ≥ 15 mm in one or more left ventricular myocardium segments, according to the results of any imaging technique that is not explained solely due to increased pressure load. For decades, echocardiography has been the first-line method in the diagnosis of HCM. This is due to its availability, low cost, and informative content. However, due to the high spatial resolution and volumetric nature of image acquisition, magnetic resonance imaging (MRI) has advantages over other diagnostic techniques. Currently, cardiac MRI is becoming the method of choice in diagnostics and management in patients with HCM. This article presents the possibilities of MR imaging in patients with HCM and demonstrates the typical phenotypes and some morphological characteristics of HCM according to our research protocols conducted on a MR scanner with a 1,5 T magnetic field strength. In addition, the article shows the clinical significance of MRI for the management of patients with HCM.
High Lifetime Risk of Cancer in the Patients with Low Lipoprotein(a) Concentration Suggests a Possible Risk of Lipoprotein(a)-lowering Therapy
Authors: Sawabe Motoji, Tanaka Noriko, Nakahara Ken-ichi, Matsushita Satoru, Hamamatsu Akihiko, Chida Koji, Harada Kazumasa, Ozawa Toshio
Journal: Circulation (2011)
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma
Authors: Hai-Feng Zhang, Christopher S. Hughes, Wei Li, Jian-Zhong He, Didier Surdez, Amal M. El-Naggar, Hongwei Cheng, Anna Prudova, Alberto Delaidelli, Gian Luca Negri, Xiaojun Li, Maj Sofie Ørum-Madsen, Michael M. Lizardo, Htoo Zarni Oo, Shane Colborne, Taras Shyp, Renata Scopim-Ribeiro, Colin A. Hammond, Anne-Chloe Dhez, Sofya Langman, Jonathan K.M. Lim, Sonia H.Y. Kung, Amy Li, Anne Steino, Mads Daugaard, Seth J. Parker, Ramon I. Klein Geltink, Rimas J. Orentas, Li-Yan Xu, Gregg B. Morin, Olivier Delattre, Dimiter S. Dimitrov, Poul H. Sorensen
Journal: Cancer Discovery (2021)

Abstract Cancer cells must overcome anoikis (detachment-induced death) to successfully metastasize. Using proteomic screens, we found that distinct oncoproteins upregulate IL1 receptor accessory protein (IL1RAP) to suppress anoikis. IL1RAP is directly induced by oncogenic fusions of Ewing sarcoma, a highly metastatic childhood sarcoma. IL1RAP inactivation triggers anoikis and impedes metastatic dissemination of Ewing sarcoma cells. Mechanistically, IL1RAP binds the cell-surface system Xc− transporter to enhance exogenous cystine uptake, thereby replenishing cysteine and the glutathione antioxidant. Under cystine depletion, IL1RAP induces cystathionine gamma lyase (CTH) to activate the transsulfuration pathway for de novo cysteine synthesis. Therefore, IL1RAP maintains cyst(e)ine and glutathione pools, which are vital for redox homeostasis and anoikis resistance. IL1RAP is minimally expressed in pediatric and adult normal tissues, and human anti-IL1RAP antibodies induce potent antibody-dependent cellular cytotoxicity of Ewing sarcoma cells. Therefore, we define IL1RAP as a new cell-surface target in Ewing sarcoma, which is potentially exploitable for immunotherapy. Significance: Here, we identify cell-surface protein IL1RAP as a key driver of metastasis in Ewing sarcoma, a highly aggressive childhood sarcoma. Minimal expression in pediatric and adult normal tissues nominates IL1RAP as a promising target for immunotherapy. See related commentary by Yoon and DeNicola, p. 2679 . This article is highlighted in the In This Issue feature, p. 2659
Abstract 15225: Remote Monitoring Using Implantable Cardiac Defibrillators for Heart Failure Management in a European Cohort: A Meta-analysis
Authors: Fredrick M Ogugua, Abdulrahman Gamam, Basilio Addo, Kofi Osei
Journal: Circulation (2020)

Introduction: Remote monitoring (RM) using implantable cardiac defibrillators (ICD) is a rapidly emerging alternative modality in heart failure management. Studies involving US cohorts have shown promising results with RM. We aim to perform a meta-analysis assessing the clinical outcomes of RM versus conventional follow-up among heart failure (HF) patients with an ICD in a European cohort. Methods: Electronic database and reference list searches were conducted to identify European studies assessing patient outcomes when managed with RM using ICD versus conventional follow up. After a review of abstracts and selected full-text articles, we identified four randomized trials (RCT) for inclusion. Quality was assessed using the Cochrane Risk of Bias Tool. The primary outcome was the incidence of HF hospitalization and the secondary outcome was all-cause mortality during the follow-up period. A random-effects model was used. All analysis was performed using Cochrane Revman version 5.3. Results: Four RCT’s were included, with a total of 4504 participants. Mean follow-up time was 22 months. Rate of HF hospitalization with RM was 678 versus 680 with conventional management (RR: 0.98, 95% CI: 0.88 to 1.10, p = 0.75). All-cause mortality with RM was 252 versus 284 with conventional management (RR: 0.88, 95% CI: 0.75 to 1.03, p =0.11). Conclusions: Our study found that in a European cohort, there was no difference in the incidence of HF hospitalization or all-cause mortality among patients managed with RM using ICD and those managed with conventional care. Further research is required to assess the feasibility and generalizability of HF management using ICD’s in different patient populations.
Activation of T Cells Specific to Endogenous Retroviral Peptides: Possible Association with Clinical Response to Azacitidine in Myeloid Malignancies
Authors: Andreas Due Ørskov, Sunil Kumar Saini, Anne-Mette Bjerregaard, Hitoshi Otani, Staffan Holmberg, Jakob Werner Hansen, Marianne Bach Treppendahl, Anne Ortved Gang, Inge Høgh Dufva, Gangning Liang, Aron Charles Eklund, Peter A. Jones, Kirsten Grønbæk, Sine Reker Hadrup
Journal: Blood (2017)